Abstract:Multiple sclerosis [MS] is a progressive autoimmune condition that primarily affects young people and is characterized by demyelination and neurodegeneration of the central nervous system [CNS]. This in-depth review explores the complex involvement of oligodendrocytes, the primary myelin- producing cells in the CNS, in the pathophysiology of MS. It discusses the biochemical processes and signalling pathways required for oligodendrocytes to function and remain alive, as well as how they might fail and cause demyelination to occur. We investigate developing therapeutic options that target remyelination, a fundamental component of MS treatment. Remyelination approaches promote the survival and differentiation of oligodendrocyte precursor cells [OPCs], restoring myelin sheaths. This improves nerve fibre function and may prevent MS from worsening. We examine crucial parameters influencing remyelination success, such as OPC density, ageing, and signalling pathway regulation [e.g., Retinoid X receptor, LINGO-1, Notch]. The review also examines existing neuroprotective and antiinflammatory medications being studied to see if they can assist oligodendrocytes in surviving and reducing the severity of MS symptoms. The review focuses on medicines that target the myelin metabolism in oligodendrocytes. Altering oligodendrocyte metabolism has been linked to reversing demyelination and improving MS patient outcomes through various mechanisms. We also explore potential breakthroughs, including innovative antisense technologies, deep brain stimulation, and the impact of gut health and exercise on MS development. The article discusses the possibility of personalized medicine in MS therapy, emphasizing the importance of specific medicines based on individual molecular profiles. The study emphasizes the need for reliable biomarkers and improved imaging tools for monitoring disease progression and therapy response. Finally, this review focuses on the importance of oligodendrocytes in MS and the potential for remyelination therapy. It also underlines the importance of continued research to develop more effective treatment regimens, taking into account the complexities of MS pathology and the different factors that influence disease progression and treatment.

Functional Role of DDR1 in Oligodendrocyte Signaling Mechanism in Association with Myelination and Remyelination Process in the Central Nerve System

Integrative Systems and Functional Analyses Reveal a Role of Dopaminergic Signaling in Myelin Pathogenesis.

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Wnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?

Demyelination-remyelination in the Central Nervous System: Ligand-dependent Participation of the Notch Signaling Pathway

A novel in vitro model for investigating oligodendroglial maturation and myelin deposition under demyelinating and remyelinating conditions: Impact of microglial depletion and repopulation

A Functional Role of NMDA Receptor in Regulating the Differentiation of Oligodendrocyte Precursor Cells and Remyelination.

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

An Ex-Vivo Multiple Sclerosis Model of Inflammatory Demyelination Using Hyperbranched Polymer

Mechanisms Governing Oligodendrocyte Viability in Multiple Sclerosis and Its Animal Models

Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

Preventing production of new oligodendrocytes impairs remyelination and sustains behavioural deficits after demyelination

Evidence That DDR1 Promotes Oligodendrocyte Differentiation during Development and Myelin Repair after Injury

Remyelination protects neurons from DLK-mediated neurodegeneration

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases

M2 Microglia and Macrophages Drive Oligodendrocyte Differentiation During CNS Remyelination